Clinical Cancer Research AACR Conference on Cancer Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grotzer, M. A.
Right arrow Articles by Phillips, P. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grotzer, M. A.
Right arrow Articles by Phillips, P. C.
Clinical Cancer Research Vol. 7, 2425-2433, August 2001
© 2001 American Association for Cancer Research

Regular Articles

MYC Messenger RNA Expression Predicts Survival Outcome in Childhood Primitive Neuroectodermal Tumor/Medulloblastoma1

Michael A. Grotzer2, Michael D. Hogarty, Anna J. Janss, Xueyuan Liu, Huaquing Zhao, Angelika Eggert, Leslie N. Sutton, Lucy B. Rorke, Garrett M. Brodeur and Peter C. Phillips

Divisions of Oncology [M. A. G., M. D. H., A. J. J., X. L., A. E., G. M. B., P. C. P.] and Biostatistics [H. Z.] and Departments of Neurosurgery [L. N. S.] and Pathology [L. B. R.], The Children’s Hospital of Philadelphia, Pennsylvania 19104

Purpose and Experimental Design: Cerebellar primitive neuroectodermal tumors/medulloblastomas (PNET/MB) are the most common malignant brain tumors in childhood. To identify PNET/MB biological prognostic factors that define a patient group with a sufficiently good prognosis to permit a reduction in treatment intensity, we determined the expression levels of MYC mRNA in fresh frozen tumor samples from 26 PNET/MB patients using semiquantitative reverse transcription-PCR.

Results: MYC mRNA expression levels in primary PNET/MB showed a wide range with a 22-fold difference between the highest and lowest values and did not correlate with MYC gene amplification. MYC mRNA expression was an independent significant prognostic factor for progression-free survival outcome and was more predictive than standard clinical factors. The combination of low MYC mRNA expression and high TrkC mRNA expression identified a good outcome group of PNET/MB patients (n = 7) with 100% progression-free survival after a median follow-up time of 55 months (range, 15–91 months). Three of these seven good outcome patients survived without radiotherapy.

Conclusions: Low MYC mRNA expression is a powerful independent predictor of favorable clinical outcome in PNET/MB. Assessment of MYC mRNA levels is feasible and may be incorporated in prospective PNET/MB clinical trials to aid in treatment planning for patients with PNET/MB on confirmation of our results in larger studies.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
T. de Haas, N. Hasselt, D. Troost, H. Caron, M. Popovic, L. Zadravec-Zaletel, W. Grajkowska, M. Perek, M.-C. Osterheld, D. Ellison, et al.
Molecular Risk Stratification of Medulloblastoma Patients Based on Immunohistochemical Analysis of MYC, LDHB, and CCNB1 Expression
Clin. Cancer Res., July 1, 2008; 14(13): 4154 - 4160.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
X. Fan and C. G. Eberhart
Medulloblastoma Stem Cells
J. Clin. Oncol., June 10, 2008; 26(17): 2821 - 2827.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Rutkowski, A. von Bueren, K. von Hoff, W. Hartmann, T. Shalaby, F. Deinlein, M. Warmuth-Metz, N. Soerensen, A. Emser, U. Bode, et al.
Prognostic Relevance of Clinical and Biological Risk Factors in Childhood Medulloblastoma: Results of Patients Treated in the Prospective Multicenter Trial HIT'91
Clin. Cancer Res., May 1, 2007; 13(9): 2651 - 2657.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. J. Packer, A. Gajjar, G. Vezina, L. Rorke-Adams, P. C. Burger, P. L. Robertson, L. Bayer, D. LaFond, B. R. Donahue, M. H. Marymont, et al.
Phase III Study of Craniospinal Radiation Therapy Followed by Adjuvant Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma
J. Clin. Oncol., September 1, 2006; 24(25): 4202 - 4208.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
X. Su, V. Gopalakrishnan, D. Stearns, K. Aldape, F. F. Lang, G. Fuller, E. Snyder, C. G. Eberhart, and S. Majumder
Abnormal Expression of REST/NRSF and Myc in Neural Stem/Progenitor Cells Causes Cerebellar Tumors by Blocking Neuronal Differentiation.
Mol. Cell. Biol., March 1, 2006; 26(5): 1666 - 1678.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Stearns, A. Chaudhry, T. W. Abel, P. C. Burger, C. V. Dang, and C. G. Eberhart
c-Myc Overexpression Causes Anaplasia in Medulloblastoma
Cancer Res., January 15, 2006; 66(2): 673 - 681.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Mendrzyk, B. Radlwimmer, S. Joos, F. Kokocinski, A. Benner, D. E. Stange, K. Neben, H. Fiegler, N. P. Carter, G. Reifenberger, et al.
Genomic and Protein Expression Profiling Identifies CDK6 As Novel Independent Prognostic Marker in Medulloblastoma
J. Clin. Oncol., December 1, 2005; 23(34): 8853 - 8862.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. R. Geyer, R. Sposto, M. Jennings, J. M. Boyett, R. A. Axtell, D. Breiger, E. Broxson, B. Donahue, J. L. Finlay, J. W. Goldwein, et al.
Multiagent Chemotherapy and Deferred Radiotherapy in Infants With Malignant Brain Tumors: A Report From the Children's Cancer Group
J. Clin. Oncol., October 20, 2005; 23(30): 7621 - 7631.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Huang, C. S.W. Ho, R. Ponzielli, D. Barsyte-Lovejoy, E. Bouffet, D. Picard, C. E. Hawkins, and L. Z. Penn
Identification of a Novel c-Myc Protein Interactor, JPO2, with Transforming Activity in Medulloblastoma Cells
Cancer Res., July 1, 2005; 65(13): 5607 - 5619.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. Pan, M. Pellarin, E. Holmes, I. Smirnov, A. Misra, C. G. Eberhart, P. C. Burger, J. A. Biegel, and B. G. Feuerstein
Isochromosome 17q Is a Negative Prognostic Factor in Poor-Risk Childhood Medulloblastoma Patients
Clin. Cancer Res., July 1, 2005; 11(13): 4733 - 4740.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. Williamson, Y.-J. Lu, T. Gordon, R. Sciot, A. Kelsey, C. Fisher, C. Poremba, J. Anderson, K. Pritchard-Jones, and J. Shipley
Relationship Between MYCN Copy Number and Expression in Rhabdomyosarcomas and Correlation With Adverse Prognosis in the Alveolar Subtype
J. Clin. Oncol., February 1, 2005; 23(4): 880 - 888.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Ray, M. Ho, J. Ma, R. K. Parkes, T. G. Mainprize, S. Ueda, J. McLaughlin, E. Bouffet, J. T. Rutka, and C. E. Hawkins
A Clinicobiological Model Predicting Survival in Medulloblastoma
Clin. Cancer Res., November 15, 2004; 10(22): 7613 - 7620.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. R. Hallahan, J. I. Pritchard, S. Hansen, M. Benson, J. Stoeck, B. A. Hatton, T. L. Russell, R. G. Ellenbogen, I. D. Bernstein, P. A. Beachy, et al.
The SmoA1 Mouse Model Reveals That Notch Signaling Is Critical for the Growth and Survival of Sonic Hedgehog-Induced Medulloblastomas
Cancer Res., November 1, 2004; 64(21): 7794 - 7800.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. M. Lamont, C. S. McManamy, A. D. Pearson, S. C. Clifford, and D. W. Ellison
Combined Histopathological and Molecular Cytogenetic Stratification of Medulloblastoma Patients
Clin. Cancer Res., August 15, 2004; 10(16): 5482 - 5493.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
O. Ozen, B. Krebs, B. Hemmerlein, A. Pekrun, H. Kretzschmar, and J. Herms
Expression of Matrix Metalloproteinases and Their Inhibitors in Medulloblastomas and Their Prognostic Relevance
Clin. Cancer Res., July 15, 2004; 10(14): 4746 - 4753.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
V P Collins
Brain tumours: classification and genes
J. Neurol. Neurosurg. Psychiatry, June 1, 2004; 75(suppl_2): ii2 - ii11.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Neben, A. Korshunov, A. Benner, G. Wrobel, M. Hahn, F. Kokocinski, A. Golanov, S. Joos, and P. Lichter
Microarray-Based Screening for Molecular Markers in Medulloblastoma Revealed STK15 as Independent Predictor for Survival
Cancer Res., May 1, 2004; 64(9): 3103 - 3111.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Gajjar, R. Hernan, M. Kocak, C. Fuller, Y. Lee, P. J. McKinnon, D. Wallace, C. Lau, M. Chintagumpala, D. M. Ashley, et al.
Clinical, Histopathologic, and Molecular Markers of Prognosis: Toward a New Disease Risk Stratification System for Medulloblastoma
J. Clin. Oncol., March 15, 2004; 22(6): 984 - 993.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. G. Fisher, P. C. Burger, and C. G. Eberhart
Biologic Risk Stratification of Medulloblastoma: The Real Time Is Now
J. Clin. Oncol., March 15, 2004; 22(6): 971 - 974.
[Full Text] [PDF]

Home page
 Neuro OncolHome page
D. Didiano, T. Shalaby, D. Lang, and M. A. Grotzer
Telomere maintenance in childhood primitive neuroectodermal brain tumors
Neuro-oncol, January 1, 2004; 6(1): 1 - 8.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Pingoud-Meier, D. Lang, A. J. Janss, L. B. Rorke, P. C. Phillips, T. Shalaby, and M. A. Grotzer
Loss of Caspase-8 Protein Expression Correlates with Unfavorable Survival Outcome in Childhood Medulloblastoma
Clin. Cancer Res., December 15, 2003; 9(17): 6401 - 6409.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I-M. Siu, A. Lal, J. R. Blankenship, N. Aldosari, and G. J. Riggins
c-Myc Promoter Activation in Medulloblastoma
Cancer Res., August 15, 2003; 63(16): 4773 - 4776.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
X. Fan, Y. Wang, J. Kratz, D. J. Brat, Y. Robitaille, A. Moghrabi, E. J. Perlman, C. V. Dang, P. C. Burger, and C. G. Eberhart
hTERT Gene Amplification and Increased mRNA Expression in Central Nervous System Embryonal Tumors
Am. J. Pathol., June 1, 2003; 162(6): 1763 - 1769.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
T. J. MacDonald, B. R. Rood, M. R. Santi, G. Vezina, K. Bingaman, P. H. Cogen, and R. J. Packer
Advances in the Diagnosis, Molecular Genetics, and Treatment of Pediatric Embryonal CNS Tumors
Oncologist, April 1, 2003; 8(2): 174 - 186.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.